We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$333M
AUM Growth
+$77.5M
Cap. Flow
+$78M
Cap. Flow %
23.42%
Top 10 Hldgs %
35.62%
Holding
104
New
20
Increased
33
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$11M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$7.71M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.79M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$4.71M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$3.07M
4
ZBH icon
Zimmer Biomet
ZBH
+$2.8M
5
AET
Aetna Inc
AET
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$162B
$17.6M 5.29%
248,735
+139,735
+128% +$11M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$17M 5.1%
111,731
+61,731
+123% +$9.82M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$16.8M 5.03%
55,792
+18,792
+51% +$5.79M
BIIB icon
4
Biogen
BIIB
$30B
$12.6M 3.77%
41,048
+14,048
+52% +$4.46M
PFE icon
5
Pfizer
PFE
$143B
$11.3M 3.4%
+372,050
New +$11.1M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.91M 2.97%
145,264
+45,264
+45% +$3.34M
PCYC
7
DELISTED
PHARMACYCLICS INC
PCYC
$9.75M 2.93%
97,286
+37,286
+62% +$4.85M
ALKS icon
8
Alkermes
ALKS
$8.22B
$8.87M 2.66%
201,277
+56,277
+39% +$2.68M
CELG
9
DELISTED
Celgene Corp
CELG
$8.15M 2.45%
116,782
+18,782
+19% +$1.49M
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
$6.73M 2.02%
+209,010
New +$7.71M
CVS icon
11
CVS Health
CVS
$133B
$6.62M 1.99%
88,442
-18,558
-17% -$1.31M
INCY icon
12
Incyte
INCY
$24.2B
$5.73M 1.72%
107,038
+22,038
+26% +$1.37M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$40.8B
$5.7M 1.71%
107,922
+42,922
+66% +$1.98M
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$5.57M 1.67%
53,788
-1,212
-2% -$124K
CFNL
15
DELISTED
Cardinal Financial Corp
CFNL
$5.03M 1.51%
+71,909
New +$1.27M
NPSP
16
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$5M 1.5%
166,970
-73,030
-30% -$2.52M
JNJ icon
17
CALL
Johnson & Johnson
JNJ
$618B
$4.91M 1.47%
50,000
– –
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$4.52M 1.36%
265,325
-134,675
-34% -$2.03M
FRX
19
DELISTED
FOREST LABORATORIES INC
FRX
$4.44M 1.33%
48,152
-6,848
-12% -$553K
ABBV icon
20
AbbVie
ABBV
$443B
$4.39M 1.32%
+85,494
New +$4.32M
MRK icon
21
Merck
MRK
$322B
$4.35M 1.31%
80,329
-8,751
-10% -$453K
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$4.43B
$4.3M 1.29%
176,883
+91,883
+108% +$2.32M
SYK icon
23
Stryker
SYK
$125B
$4.16M 1.25%
+51,100
New +$4.06M
CYBX
24
DELISTED
CYBERONICS INC
CYBX
$4.16M 1.25%
63,754
+23,754
+59% +$1.6M
TMO icon
25
Thermo Fisher Scientific
TMO
$213B
$4.14M 1.24%
34,394
+9,394
+38% +$1.12M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rhenman & Partners Asset Management held 104 positions worth $333M, up 30% from $256M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rhenman & Partners Asset Management deployed $78M of net new capital in Q1 2014, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Pfizer: 372,050 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 83% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $3.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2014 buy was Pfizer: 372,050 shares worth $11.3M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q1 2014, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $3.6M.
  • Rhenman & Partners Asset Management fully exited Innoviva in Q1 2014, selling an estimated $4.71M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 36% of its $333M portfolio in Q1 2014.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 13 in Q1 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $333M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2014, filed 14 May 2014.